JWA
BMRN icon

JFS Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

JFS Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.47K Buy
113
+9
+9% +$493 ﹤0.01% 1180
2026
Q1 		$5.88K Buy
104
+8
+8% +$466 ﹤0.01% 1138
2025
Q4 		$5.71K Buy
96
+54
+129% +$2.94K ﹤0.01% 1185
2025
Q3 		$2.27K Buy
42
+16
+62% +$915 ﹤0.01% 1409
2025
Q2 		$1.43K Sell
26
-44
-63% -$2.59K ﹤0.01% 1480
2025
Q1 		$4.95K Buy
70
+11
+19% +$740 ﹤0.01% 1133
2024
Q4 		$3.88K Sell
59
-35
-37% -$2.34K ﹤0.01% 1218
2024
Q3 		$6.61K Buy
94
+16
+21% +$1.34K ﹤0.01% 1013
2024
Q2 		$6.42K Sell
78
-5
-6% -$416 ﹤0.01% 959
2024
Q1 		$7.25K Sell
83
-8
-9% -$716 ﹤0.01% 935
2023
Q4 		$8.78K Buy
91
+5
+6% +$442 ﹤0.01% 814
2023
Q3 		$7.61K Hold
86
– – ﹤0.01% 820
2023
Q2 		$7.46K Sell
86
-5
-5% -$471 ﹤0.01% 833
2023
Q1 		$8.85K Sell
91
-5
-5% -$518 ﹤0.01% 754
2022
Q4 		$9.94K Buy
96
+7
+8% +$657 ﹤0.01% 717
2022
Q3 		$8K Buy
89
+8
+10% +$712 ﹤0.01% 792
2022
Q2 		$7K Buy
81
+18
+29% +$1.43K ﹤0.01% 858
2022
Q1 		$5K Buy
63
+13
+26% +$1.09K ﹤0.01% 1022
2021
Q4 		$4K Sell
50
-1,040
-95% -$85.8K ﹤0.01% 832
2021
Q3 		$84K Buy
+1,090
New +$86K 0.01% 341
2015
Q3 		– Sell
-24
Closed -$3K – 487
2015
Q2 		$3K Sell
24
-14
-37% -$1.74K ﹤0.01% 442
2015
Q1 		$5K Sell
38
-10
-21% -$1.06K ﹤0.01% 412
2014
Q4 		$4K Sell
48
-1
-2% -$83 ﹤0.01% 444
2014
Q3 		$4K Sell
49
-7
-13% -$460 ﹤0.01% 392
2014
Q2 		$3K Buy
+56
New +$3.38K ﹤0.01% 407

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JFS Wealth Advisors's BMRN Position: Q2 2026 in Review

JFS Wealth Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 8.7% in Q2 2026, buying an estimated $493 and bringing the position to 113 shares worth $6.47K. The position accounts for ﹤0.01% of the portfolio, ranked #1180.

JFS Wealth Advisors first reported a position in BMRN in Q2 2014 and has held it in 25 quarters since. The position peaked at $84K in Q3 2021. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • JFS Wealth Advisors held 113 shares of BioMarin Pharmaceuticals worth $6.47K as of Q2 2026.
  • JFS Wealth Advisors bought 9 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $493.
  • BioMarin Pharmaceuticals made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1180 holding.
  • JFS Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 25 quarters since.
  • JFS Wealth Advisors's BioMarin Pharmaceuticals position peaked at $84K in Q3 2021.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.